Navigation Links
Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
Date:11/3/2010

MORRISTOWN, N.J., Nov. 3, 2010 /PRNewswire/ -- Further to its previously announced voluntary recall of 18 lots of Fentanyl Transdermal System 25 mcg/hour C-II patches, Actavis is encouraging consumers to return any product in their possession from the October 21, 2010 recall.

Consumers with Actavis 25 mcg/h Fentanyl patches may call 1-877-422-7452 (24 hours/day, 7 days/week) for return instructions and information.

Actavis identified one lot of 25 mcg/hour Fentanyl patches (Control/Lot # 30349) shipped to market that contained one patch that released its active ingredient in laboratory testing faster than the approved specification. An accelerated release of Fentanyl from a 25 mcg/hour patch could lead to adverse events for at-risk patients such as children and the elderly, including excessive sedation, respiratory depression, hypoventilation (slow breathing), and apnea (temporary suspension of breathing).

The Control/Lot number appears on the bottom of the product box and on the black and white side of each individual patch packaging, in the lower left corner.

Recalled Control/Lot #s

30041, Exp 12/2011

30049, Exp 12/2011

30066, Exp 12/2011

30096, Exp 01/2012

30097, Exp 02/2012

30123, Exp 01/2012

30241, Exp 02/2012

30256, Exp 02/2012

30257, Exp 03/2012

30258, Exp 03/2012

30349, Exp 03/2012

30350, Exp 03/2012

30391, Exp 03/2012

30392, Exp 04/2012

30429, Exp 04/2012

30430, Exp 04/2012

30431, Exp 04/2012

30517, Exp 04/2012

Corium International Inc., a third-party supplier for Actavis, manufactured the recalled patches at its Grand Rapids, Michigan facility. The patches are packaged individually and boxed in quantities of five patches per box.

Fentanyl Transdermal System is indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate release opioids.

As part of the voluntary recall, all wholesalers and retailers were asked to return the product from the listed lots that they may still have on hand or in stock. Actavis also is encouraging consumers to return product in their possession. Fentanyl patches sold by Actavis in Europe are not impacted by the recall.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Information also is available through the Actavis U.S. website at www.actavis.us by going to the "Fentanyl Recall Information" link on the front page.

Actavis has operators available to help consumers, customers and health professionals with the following information:

  • Medical Issue/Adverse Event/Product Questions: 1-877-422-7452 (24 hours/day, 7 days/week)

  • Return/Reimbursement Questions: 1-888-896-4562 (24 hours/day, 7 days/week)

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online: www.fda.gov/medwatch/report.htm

Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.

Fax: 1-800-FDA-0178

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Sunrise, FL and Owings Mills, MD. For more information, please visit www.actavis.us .

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, more than 10,000 employees.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
2. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
3. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
4. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
5. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
6. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
7. Actavis Launches Generic Version of Flomax(R) In The U.S.
8. Actavis Receives Approval of Alprazolam ODT in the U.S.
9. NCPA Encourages Pharmacists to Promote Medication Expertise from Dispensing to Disposal
10. National Health Education Campaign: "When Will You Pick?"™ Encourages Families to Make Flu Vaccination a Priority This Fall
11. Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Inspiring Triathlete Participates in Health Fair at The Medicine Stop 5525 South Pulaski Road, Chicago Thursday, August 26, 2010, 1:00 pm - 4:00 pm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... their offering. ... separate comprehensive analytics for the US, Canada , ... , and Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Feb. 17, 2017  Featuring new ... at the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  ... a global leader in health ... of population health management, acute healthcare ... integrated in a highly secure, cloud-based ...
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
Breaking Medicine Technology:
(Date:2/17/2017)... BEAVER CREEK, CO (PRWEB) , ... February 17, 2017 , ... ... the second annual International Healing NET Foundation Summit from February 21 - 23 in ... Healing NET Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton Insurance, a Florida-based ... owners in the greater Fort Lauderdale metropolitan region, is embarking on a cooperative ... 30 years, LifeNet 4 Families has provided a broad range of food provision ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... financial planning services to families and entrepreneurs in the Birmingham area, is announcing ... mother who needs assistance with her medically challenged son, Anius. , Anius is ...
(Date:2/16/2017)... ... 16, 2017 , ... Doctors on Liens is proud to ... network through his work at BKP Chiropractic in Lancaster . After ... from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open successful ...
Breaking Medicine News(10 mins):